Myelodysplastic Syndromes
Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Melissa BadamoAcute Myeloid Leukemia | May 19, 2025
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Nichole TuckerMyelodysplastic Syndromes | May 13, 2025
Julie Braish, MBBCh, a third-year fellow at MD Anderson, presented data on azacitidine and venetoclax in HR-MDS and CMML.
Andrew MorenoAcute Myeloid Leukemia | May 9, 2025
Presented preclinical model data show significant efficacy against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Naval Daver, MDMyelodysplastic Syndromes | May 8, 2025
Naval Daver, MD, discusses the latest advancements in the treatment of myelodysplastic syndromes
Advertisement
Rahul Banerjee, MD, FACPMyelodysplastic Syndromes | May 9, 2025
At The HemOnc Pulse Live!, experts debate key controversies in MDS care, from frontline therapy to emerging treatments.
Melissa BadamoAcute Myeloid Leukemia | May 6, 2025
Mice treated with CLK3 TCR9-T cells had a significantly lower tumor burden than those who received control treatments.
Andrew Brunner, MDMyelodysplastic Syndromes | May 6, 2025
Anderw Brunner, MD addresses current gaps in MDS research and clinical practice and more.
Andrew MorenoTransplantation & Cellular Therapy | April 25, 2025
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Melissa BadamoAcute Lymphoblastic Leukemia | April 23, 2025
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Andrew MorenoAcute Myeloid Leukemia | April 22, 2025
The investigational small molecule enzomenib has received FDA Orphan Drug and Fast Track designations in AML.
Melissa BadamoPrint | April 14, 2025
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Melissa BadamoAcute Lymphoblastic Leukemia | April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Andrew MorenoMyelodysplastic Syndromes | April 2, 2025
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Andrew MorenoTransplantation & Cellular Therapy | March 31, 2025
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Melissa BadamoAcute Lymphoblastic Leukemia | March 14, 2025
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Melissa BadamoMyelodysplastic Syndromes | March 13, 2025
The approval was based on the phase 3 IMerge study, which showed improved rates of transfusion independence with imetelstat.
Melissa BadamoMyelodysplastic Syndromes | February 28, 2025
MRD testing before HSCT may offer insight into survival outcomes for patients with MDS/MPN.
Andrew MorenoAcute Myeloid Leukemia | February 25, 2025
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
Advertisement
Advertisement